Top 10 ETF Picks for August 2025: Best Funds to Buy Now for Growth, Safety, and Diversification

By -
Here are the top 10 ETF picks for August 2025, along with insights on whether they are worth considering for investment right now. This list blends global equity leaders, sector specialists in defense and metals, and broad market trackers—balancing momentum with diversification and risk management.
Current market conditions and upcoming events like the U.S. Federal Reserve’s September meeting make August a timely opportunity to reallocate or accumulate:

1. SPDR S&P 500 ETF Trust (SPY) or Vanguard S&P 500 ETF (VOO)

  • Broad U.S. equity exposure; strong performers with SPY up 8.9% YTD and focused on the AI rally and potential post-rate-cut growth (1, 2). Would buy: Yes, for long-term core holding and growth.

2. iShares Core S&P 500 ETF (IVV)

  • Similar to SPY/VOO, highly liquid, low expense ratio. Would buy: Yes, for passive U.S. equity exposure (2).

3. Mirae Asset Defence Tech ETF or MarketVector Global Defense Industry ETF

  • Defense sector ETFs are up 45%–60% in 2025 (YTD) on geopolitical risk and rising government spending on security/defense (3, 4). Would buy: Yes, for sector momentum and hedge benefits.

4. DAXglobal Gold Miners or VanEck Gold Miners ETF (GDX)

  • Gold/silver miners are up 34%–47% YTD, fueled by record gold prices and institutional inflows. Would buy: Yes, as leveraged play on safe-haven demand and inflation hedging (3)

5. iShares Gold Trust (IAU) or SPDR Gold MiniShares (GLDM)

  • Physical gold ETFs with 1-year returns above 40%, providing excellent insurance and uncorrelated returns amid macro uncertainty (4). Would buy: Yes, as a portfolio hedge and inflation buffer.

6. Solactive Global Silver Miners ETF

  • Silver ETFs and miners up to 34% YTD, driven by industrial demand and precious metal price spikes (3, 5). Would buy: Yes, for metals exposure and diversified inflation protection (2).

7. Betashares Global Quality Leaders ETF (ASX: QLTY)

  • Focused on companies with high returns on equity and low debt globally; good for stability in volatile markets (5). Would buy: Yes, for defensive growth.

8. iShares MSCI Poland ETF (EPOL) & Other Emerging Market Leaders

  • Poland, Greece, Brazil, and Korea ETFs have outperformed due to regional economic upswings, government reforms, and global reallocation (6, 3). Would buy: Yes, for regional diversification and emerging market alpha.

9. BlackRock iShares Bitcoin Trust (IBIT) or Fidelity Bitcoin ETF (FBTC)

  • Spot Bitcoin ETFs with strong retail and institutional flows, up over 60% YTD, offering digital asset exposure in regulated wrappers (7). Would buy: Consider for risk-tolerant investors seeking diversification.

10. BMO Equal Weight Global Base Metals ETF (ZMT)

  • Up 21.6% last quarter; metals ETFs benefit from global infrastructure, green energy demand, and supply constraints in commodities (8). Would buy: Yes, for exposure to global economic and industrial growth.

Would I buy today (August 2025)?

Yes—many of these ETFs remain strong “buys” for diversified portfolios, given robust sector momentum and macro trends for inflation, defense spending, technological innovation, commodities, and emerging markets. August is considered a strategic “accumulation window” before the Fed’s September rate decision, offering a chance to position portfolios for a potential risk-on rally or continued protection.

As always, match selection to your time horizon, risk tolerance, and investment goals. Keep an eye on macro headlines and be prepared for volatility in the coming months.

References:

  1. https://www.bankrate.com/investing/best-etfs/
  2. https://finance.yahoo.com/news/best-p-500-etfs-10-121322236.html
  3. https://www.justetf.com/en/market-overview/the-best-etfs.html
  4. https://www.youtube.com/watch?v=GbX6AkjQUoo
  5. https://www.fool.com.au/2025/07/29/5-high-quality-asx-etfs-to-buy-in-august/
  6. https://money.usnews.com/investing/articles/best-performing-etfs
  7. https://www.forbes.com/sites/investor-hub/article/best-stocks-buy-now-august-2025/
  8. https://global.morningstar.com/en-ca/etfs/the-best-performing-etfs-of-the-quarter-2
  9. https://www.youtube.com/watch?v=Ld4zhcEYzSE
  10. https://www.cnbc.com/2025/08/01/stock-market-next-week-live-updates-for-august-4-8-2025.html
  11. https://finance.yahoo.com/news/3-vanguard-etfs-buy-1-141500837.html
  12. https://finance.yahoo.com/news/5-etf-predictions-second-half-140000444.html
  13. https://www.nerdwallet.com/article/investing/sp-500-etfs
  14. https://money.usnews.com/investing/articles/best-etfs-to-buy-for-long-term-investors
  15. https://www.trustnet.com/news/13454770/the-best-and-worst-funds-in-july
  16. https://seekingalpha.com/article/4807814-rsp-sp500-monthly-dashboard-august-2025
  17. https://finance.yahoo.com/news/1-top-dividend-etf-cant-081600635.html
  18. https://finance.yahoo.com/news/5-index-etfs-buy-1-091500656.html
  19. https://www.ssga.com/us/en/intermediary/insights/etf-trends-whats-next-for-etfs
  20. https://secure.fundsupermart.com/fsmone/article/rcms331141/etf-focus-list-2025-our-top-picks-for-the-year-ahead

Comments

Post a Comment

Pages

Popular posts from this blog

Top Gold ETFs to Watch in 2025: Best Picks for Strong Returns and Low Costs

By -
Image
Top gold ETFs to watch in 2025 span U.S., Indian, Europe and Chinese markets, offering both physical gold exposure and mining stock leverage. Based on the latest performance, expense ratios, and trends, key ETFs include: SPDR Gold MiniShares Trust (GLDM) : The best-performing gold ETF by one-year return in 2025, up around 44%, with a very low expense ratio (0.10%). It tracks physical gold closely and is highly liquid, making it a top choice for cost-conscious investors seeking strong recent gains ( 2 ,  1 ). iShares Gold Trust Micro (IAUM) : Nearly matching GLDM’s performance with a 43.86% one-year gain and an even lower expense ratio (0.09%), this is an excellent low-cost option for gold exposure ( 2 ). abrdn Physical Gold Shares ETF (SGOL) : With about a 43.8% one-year return and expense ratio around 0.17%, this fund holds physical gold bullion and appeals to investors seeking stable, direct gold exposure ( 2 ,  1 ). GraniteShares Gold Trust (BAR) : Tracks physica...
Read more

Best Gold and Silver ETFs of 2025: Should You Buy Today?

By -
Image
Gold and silver ETFs are outperforming the S&P 500 index. But do these precious metals deserve a place in your investment portfolio? We provide a list of the best precious metals ETFs by 2025 performance, as well as the benefits and risks that investors need to know before buying these funds.  The best gold and silver ETFs of 2025 stand out due to exceptional performance, low expense ratios, and reliable tracking of precious metals’ prices. Here are the top options across global and key regional markets as of July 2025: Best Gold ETFs of 2025 SPDR Gold MiniShares Trust (GLDM) 1-Year Return: 43.90% Expense Ratio: 0.10% Notes: Best performing gold ETF, tracks physical gold, high liquidity, and cost-effective for retail investors ( 1 ,  2 ). iShares Gold Trust Micro (IAUM) 1-Year Return: 43.86% Expense Ratio: 0.09% Notes: Nearly matches GLDM in returns, with the lowest expense ratio among major gold ETFs ( 1 ). abrdn Physical Gold Shares ETF (S...
Read more

Top XRP ETFs to Watch in 2025: Dominating Holdings, Low Fees, and Performance Insights

By -
Image
As the cryptocurrency market matures in 2025, XRP ETFs have emerged as essential instruments for investors seeking regulated and accessible exposure to this dynamic digital asset. With a growing variety of futures-based and physically backed spot ETFs now available across major markets like the U.S., Canada, and Europe, understanding the nuances of these products—including their fee structures, holdings, and performance—is crucial for making informed investment decisions. This article highlights the top XRP ETFs to watch in 2025, providing deep insights into their dominating holdings, low fees, and recent market impact, all organized in a clear list format for easy navigation. Whether you are a long-term investor or an active trader, this guide will help you identify opportunities and risks in the evolving XRP ETF landscape. 1. Leading XRP ETFs in 2025 ProShares Ultra XRP ETF (UXRP) Type: 2x leveraged futures-based ETF listed in the U.S. Launched: July 18, 2025 Key Features...
Read more

Top 10 Pharma Companies by Market Cap in 2025

By -
Image
Here are the top 10 pharmaceutical companies by market cap as of July 2025. The pharmaceutical industry remains robust amid evolving market dynamics, driven by innovation, strategic expansions, and shifting healthcare policies. This mid-2025 update integrates the first half's (H1) financial results to provide readers with a clear snapshot of leading companies’ performance and trajectory. Aug 1, 2025 Update:  @POTUS  sent letters to 17 drug manufacturers outlining steps they must take to bring down prescription drug prices. ( source ) In contrast, most of the other top 10 pharmaceutical companies are expected to see more moderate revenue growth, generally in the range of 6% to 9% by the end of 2025. This reflects steady but less dramatic expansion compared to Eli Lilly’s exceptional performance ( 4 ). Credit: CompaniesMarketCap.com ...
Read more

Top 10 Cancer Drug Companies of 2025

By -
Image
Merck, Roche and Celgene (now part of Bristol-Myers Squibb) have remained prominent players, but the market dynamics have shifted significantly in recent years. Aug 1, 2025 Update:  @POTUS  sent letters to 17 drug manufacturers outlining steps they must take to bring down prescription drug prices. ( source ) This increased competition is fueled by the success of blockbuster drugs like Keytruda (Merck), Tagrisso (AstraZeneca), and Ibrance (Pfizer), as well as the rapid adoption of immunotherapies and targeted treatments ( Verified Market Reports ). Look at 2017. The trio of drugmakers together held a 45.8% share of the market, with longtime cancer leader Roche controlling 26.4% all on its own. In 2024, though, market intelligence firm EvaluatePharma expects to see much more parity. The top three’s share will shrink to 26.2%, with Roche’s dropping all the way down to 11.9%. And the No. 2 through No. 5 companies—BMS, Johnson & Johnson, Pfizer, AstraZeneca and Merck—will boas...
Read more

Top 10 Pharmaceutical Companies by Revenue in 2025 (July Edition)

By -
Image
Here are the top 10 pharmaceutical companies by revenue as of 2025, primarily based on first quarter 2025 revenue data. Only one of the top 10 drugmakers, Eli Lilly, is expected to achieve a double-digit revenue increase by the end of 2025. Eli Lilly is projecting a robust growth of around 32% in 2025 compared to 2024, driven by strong sales of its diabetes and weight-loss drugs such as Mounjaro and Zepbound, with full-year revenue guidance between $58 billion and $61 billion ( 1 ,  2 ,  3 ). Aug 1, 2025 Update:  @POTUS sent letters to 17 drug manufacturers outlining steps they must take to bring down prescription drug prices. ( source ) In contrast, most of the other top 10 pharmaceutical companies are expected to see more moderate revenue growth, generally in the range of 6% to 9% by the end of 2025. This reflects steady but less dramatic expansion compared to Eli Lilly’s exceptional performance ( 4 ). While earnings and revenue reports are considered lagging indicator...
Read more

We Asked Grok 3 to Predict the Market: Stocks, Bitcoin and More (July 2025 Edition)

By -
Image
Predicting what will happen in the markets is difficult, so we decided to see what AI had to say. We asked Grok 3 what July 2025 has in store for stocks, bitcoin, and more. Many try but few succeed in correctly predicting the markets — even among Wall Street analysts who do it for a living. Take the S&P 500, for example. The index closed 2024 at 5,882, cementing a second year of more than 20% gains. Yet at this time last year, Wall Street's 2024 median year-end price target was just 4,850, according to Bloomberg data. Not exactly close. Since experts are so often wrong, we figured it wouldn't be a bad idea to put Big Tech's trillion-dollar baby to work and ask AI for its predictions on the economy and markets going into 2025. Will Bitcoin or Nvidia go to the moon? Peak price prediction? We'll find out in next month... The S&P 500 will end the July 2025 month at 6,400. Grok 3 said:  My specific forecast, leaning toward a cautious but optimistic scenario, is 6,400...
Read more

Did Steve Jobs Refuse Treatment for Pancreatic Cancer?

By Editorial Team -
Image
It’s been more than 12 years since the passing of Steve Jobs. Legendary Apple Inc., Co-founder Steve Jobs passed away at only 56 years old after battling pancreatic neuroendocrine tumor, a rare form of pancreatic cancer. A growing list of people in the public spotlight have faced pancreatic cancer, including tech innovators, entrepreneurs and influencers. In addition, and connected to Jobs, Jef Raskin, developer of the Macintosh computer, passed away of pancreatic cancer in 2005. And, coincidentally, Dag Kittlaus, creator of Siri, which was acquired by Apple in 2010, was diagnosed with the same exact cancer that took the life of Jobs. Pancreatic neuroendocrine tumors (or PNETs) account for less than 10% of all pancreatic cancer tumors and tend to grow slower than exocrine tumors, the most common type of pancreas tumors. Jobs survived eight years before dying of the disease on Oct. 5, 2011. The five-year survival rate for pancreatic cancer is only 10%. Since PNETs are so uncommon, trea...
Read more

Silicon Valley is foaming at the mouth with the promise of AI 'agents.' These are the startups to watch (2025)

By -
Image
Sam Altman, the CEO of OpenAI, has prophesied that this may be the year the first "agents" — a set of artificial intelligence tools that can perform tasks on their own — "join the workforce." Investors whose job it is to back new technologies before they become ubiquitous are swooning at the promise of these digital coworkers. The rise of agents offers fertile ground for a select group of startups to establish themselves as the front-runners of this shift. In that spirit, Business Insider reviewed press releases, news articles, and PitchBook data for startups exploring the application of agents across various sectors and then filtered for those companies that raised rounds of more than $25 million and less than $75 million in 2024. The result is a list of 20 startups that seem positioned to scale this year on the back of new funding. "If 2024 was the year of LLMs, we believe 2025 will be the year of agentic AI," said Praveen Akkiraju, a man...
Read more